RxDoctor Payments DataLook up a doctor →

Dennis Ross, MD

Nephrology · Wichita, KSNPI 1073510376

Payments from drug & device makers

$2,139,487in general payments, 2019–2025

Across 482 payments — averaging $4438.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$685K
  • AstraZeneca$492K
  • GSK$252K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$160K
  • CSL Behring$124K
  • Bayer$98K
  • plus $328K from 35 others
$2,988in research payments, 2019–2025

Across 23 payments — averaging $129.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Gilead$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,139,487 in reported general payments places this provider in the 95th percentile of 55 nephrology providers in Kansas.

See all nephrology providers in Kansas

Medicare billing

Part B allowed, 2024
$30,028
Medicare patients
91
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →